Analyst Ratings February 10, 2026

UBS Lifts Corpay Price Target to $380, Cites Strong Guidance and Strategic Shifts

Analyst keeps Neutral rating as company guidance, recent results and acquisitions underpin outlook

By Ajmal Hussain CPAY
UBS Lifts Corpay Price Target to $380, Cites Strong Guidance and Strategic Shifts
CPAY

UBS raised its price target on Corpay to $380 from $315 while retaining a Neutral rating. The upgrade reflects Corpay’s formal 2026 guidance for 10% organic revenue growth, a projected 22% adjusted EPS increase at the midpoint, recent fourth-quarter results that beat estimates, and expected accretion from recent acquisitions.

Key Points

  • UBS raised its Corpay price target to $380 and maintained a Neutral rating; analyst targets range from $340 to $440.
  • Corpay issued formal 2026 guidance calling for 10% organic revenue growth and projected 22% adjusted EPS growth at the midpoint.
  • Q4 2025 results beat expectations: EPS $6.04 vs $5.93 forecast and revenue $1.25 billion vs $1.23 billion forecast; stock climbed 21.79% over the prior week.

UBS updated its price objective for Corpay (NYSE:CPAY) to $380.00 from $315.00 and kept a Neutral rating on the shares. The new target sits near the upper end of analyst forecasts, which InvestingPro reports run from $340 to $440. Corpay stock was trading at $356.08 at the time of the report, and InvestingPro’s analysis described the stock as slightly undervalued.

The adjustment in UBS’s target follows Corpay’s formal guidance for 2026, in which the company expects 10% organic revenue growth. That outlook is consistent with the preliminary guidance Corpay provided alongside its third-quarter earnings, and it builds on recent top-line momentum: revenue rose 13.93% over the last twelve months.

Corpay also set a midpoint projection for adjusted EPS growth of 22%, a figure UBS linked to stable-to-strong operational trends as the company exited the fourth quarter and to a more favorable macroeconomic environment. Investor reaction to the guidance and related commentary was strong - the stock delivered a 21.79% return over the prior week.

UBS highlighted Corpay’s ongoing strategic rotation toward Corporate Payments as a contributor to the more constructive outlook. The firm additionally pointed to the accretive impact expected from Corpay’s acquisitions of Alpha Group and AvidXChange, noting those deals are anticipated to add $1.00 in cash EPS accretion.

Recent company results provided further context for UBS’s move. In the fourth quarter of 2025 Corpay reported adjusted earnings per share of $6.04, ahead of the analyst consensus of $5.93. Revenue for the quarter came in at $1.25 billion, beating the anticipated $1.23 billion. The company also extended a multi-year agreement with Rugby Australia, remaining its Official Foreign Exchange Payments Partner and collaborating exclusively with both the men’s and women’s Australian National Rugby Union Teams.

Taken together, these elements - formalized 2026 guidance, stronger-than-expected quarterly results, acquisition-driven EPS accretion expectations, and the strategic emphasis on Corporate Payments - explain UBS’s decision to raise the target even while maintaining a Neutral stance. The outlook reflects a combination of management guidance, recent financial performance, and planned deal contributions rather than a change in the firm’s near-term rating.

Investors and market participants will likely watch execution closely: the company’s growth and EPS trajectory are tied to management’s guidance, the contribution from recent acquisitions, and the broader macroeconomic backdrop referenced by both Corpay and UBS.


Summary

UBS increased its Corpay price target to $380 from $315 and retained a Neutral rating. The move references Corpay’s 2026 guidance for 10% organic revenue growth, a projected 22% adjusted EPS increase at the midpoint, recent quarterly results that beat analyst estimates, and expected accretion from acquisitions.

Key points

  • UBS raised its price target to $380 and kept a Neutral rating; analyst targets range from $340 to $440.
  • Corpay issued formal 2026 guidance calling for 10% organic revenue growth and projected 22% adjusted EPS growth at the midpoint.
  • Q4 2025 results exceeded forecasts with EPS of $6.04 versus $5.93 expected and revenue of $1.25 billion versus $1.23 billion expected; the stock rose 21.79% over the prior week.
  • Strategic moves - a rotation toward Corporate Payments and the acquisitions of Alpha Group and AvidXChange - are expected to add $1.00 in cash EPS accretion.

Risks and uncertainties

  • Guidance risk - Corpay’s 2026 targets are projections and rely on execution to realize the stated 10% organic revenue growth and 22% adjusted EPS increase; this impacts financials and investor sentiment in the payments and financial services sectors.
  • Macroeconomic sensitivity - UBS’s outlook cites a more favorable macroeconomic environment as supportive; a less favorable macro backdrop could undermine the projected trends and affect the payments and corporate treasury markets.
  • Acquisition execution - anticipated accretion from Alpha Group and AvidXChange is expected but not guaranteed; integration or performance shortfalls would affect expected EPS contribution and M&A outcomes in the payments space.

Risks

  • Guidance risk: achievement of the 10% organic revenue growth and 22% adjusted EPS guidance depends on execution, affecting the payments and financial services sectors.
  • Macroeconomic sensitivity: a less favorable macro environment than referenced could weaken projected trends, impacting corporate payments and treasury markets.
  • Acquisition execution risk: expected $1.00 cash EPS accretion from Alpha Group and AvidXChange depends on successful integration and performance, affecting M&A outcomes in payments.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026